At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) for Depressive Disorder, Major Depressive Disorder. Completed, enrolled 40 participants across 9 sites.
Detailed Summary
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder. A secondary aim is to evaluate the efficacy of DVS SR in the treatment of child and adolescent outpatients with major depressive disorder in an exploratory manner.
Study Details
Timeline
Interventions
* tablet * subjects randomly assigned to 10-200 mg/day by age group * 6 month treatment period(\~182 days)